Benign and Malignant Adrenal Gland Surgery: Single Center Experience (ECOADE)

May 3, 2026 updated by: DANIELE CROCETTI, University of Roma La Sapienza
PATIENTS AFFECTED BY ADRENAL GLAND DISEASE WITH SURGICAL INDICATION OF ROBOTIC OR LAPAROSCOPIC ADRENALECTOMY

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

12

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

PATIENTS AFFECTED BY ADRENAL GLAND DISEASE WHIT INDICATIONS TO ADRENALECTOMY

Description

Inclusion Criteria:

  • ADRENAL GLAND DISEASE

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
POSTOPERATIVE COMPLICATIONS
Time Frame: FROM ENROLLMENT TO THE END OF TREATMENT AT 5 YEARS
CLAVIEN-DINDO SCORE
FROM ENROLLMENT TO THE END OF TREATMENT AT 5 YEARS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Roma La Sapienza

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 3, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

May 3, 2026

First Submitted That Met QC Criteria

May 3, 2026

First Posted (Actual)

May 11, 2026

Study Record Updates

Last Update Posted (Actual)

May 11, 2026

Last Update Submitted That Met QC Criteria

May 3, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 01162026/02 (Other Identifier: SAPIENZA, UNIVERSITY OF ROME)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adrenal Gland Disease

Clinical Trials on Surgery with and without the aid of Indocyanine Green (ICG)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe